Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines - Report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies

Morag Ferguson, Suzanne Johnes, Li Li, Alan Heath, Alan Barrett

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Japanese encephalitis (JE) viruses are grouped into four genotypes. Although currently available vaccines are derived only from viruses in genotype III, vaccines are known to protect against naturally occurring strains. Studies were undertaken to assess the suitability of a freeze-dried pool of human anti-JE plasma, collected from recipients of Biken (Nakayama-NIH) killed vaccine, to serve as an International Standard for antibodies to JE virus. Five participants in five countries submitted data from 11 assays on the candidate International Standard and seven coded samples including sera from recipients of vaccines containing a range of virus strains. The results of the study indicated that the 50% plaque reduction neutralization test (PRNT50titres) obtained for serum from recipients of killed vaccines, including the candidate standard, vary depending on the virus strain used in the neutralization tests, namely higher PRNT50titres were obtained when the challenge virus was homologous to the vaccine strain compared to use of a heterologous virus. Potencies expressed relative to the candidate standard are therefore affected by the strain of virus used in assays and the use of a standard would therefore not facilitate direct comparison of data from laboratories that have used different challenge strains.

Original languageEnglish
Pages (from-to)111-116
Number of pages6
JournalBiologicals
Volume36
Issue number2
DOIs
StatePublished - Mar 2008

Fingerprint

Japanese Encephalitis Virus
Inactivated Vaccines
Vaccines
Viruses
Antibodies
Assays
Neutralization Tests
Genotype
Japanese Encephalitis Viruses
Serum

Keywords

  • Antibody
  • Japanese encephalitis virus
  • Neutralization
  • Standardization
  • Strains

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Infectious Diseases

Cite this

@article{ca38d85bbf6f481c82df6df5f0e18b21,
title = "Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines - Report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies",
abstract = "Japanese encephalitis (JE) viruses are grouped into four genotypes. Although currently available vaccines are derived only from viruses in genotype III, vaccines are known to protect against naturally occurring strains. Studies were undertaken to assess the suitability of a freeze-dried pool of human anti-JE plasma, collected from recipients of Biken (Nakayama-NIH) killed vaccine, to serve as an International Standard for antibodies to JE virus. Five participants in five countries submitted data from 11 assays on the candidate International Standard and seven coded samples including sera from recipients of vaccines containing a range of virus strains. The results of the study indicated that the 50{\%} plaque reduction neutralization test (PRNT50titres) obtained for serum from recipients of killed vaccines, including the candidate standard, vary depending on the virus strain used in the neutralization tests, namely higher PRNT50titres were obtained when the challenge virus was homologous to the vaccine strain compared to use of a heterologous virus. Potencies expressed relative to the candidate standard are therefore affected by the strain of virus used in assays and the use of a standard would therefore not facilitate direct comparison of data from laboratories that have used different challenge strains.",
keywords = "Antibody, Japanese encephalitis virus, Neutralization, Standardization, Strains",
author = "Morag Ferguson and Suzanne Johnes and Li Li and Alan Heath and Alan Barrett",
year = "2008",
month = "3",
doi = "10.1016/j.biologicals.2007.07.002",
language = "English",
volume = "36",
pages = "111--116",
journal = "Biologicals",
issn = "1045-1056",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines - Report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies

AU - Ferguson, Morag

AU - Johnes, Suzanne

AU - Li, Li

AU - Heath, Alan

AU - Barrett, Alan

PY - 2008/3

Y1 - 2008/3

N2 - Japanese encephalitis (JE) viruses are grouped into four genotypes. Although currently available vaccines are derived only from viruses in genotype III, vaccines are known to protect against naturally occurring strains. Studies were undertaken to assess the suitability of a freeze-dried pool of human anti-JE plasma, collected from recipients of Biken (Nakayama-NIH) killed vaccine, to serve as an International Standard for antibodies to JE virus. Five participants in five countries submitted data from 11 assays on the candidate International Standard and seven coded samples including sera from recipients of vaccines containing a range of virus strains. The results of the study indicated that the 50% plaque reduction neutralization test (PRNT50titres) obtained for serum from recipients of killed vaccines, including the candidate standard, vary depending on the virus strain used in the neutralization tests, namely higher PRNT50titres were obtained when the challenge virus was homologous to the vaccine strain compared to use of a heterologous virus. Potencies expressed relative to the candidate standard are therefore affected by the strain of virus used in assays and the use of a standard would therefore not facilitate direct comparison of data from laboratories that have used different challenge strains.

AB - Japanese encephalitis (JE) viruses are grouped into four genotypes. Although currently available vaccines are derived only from viruses in genotype III, vaccines are known to protect against naturally occurring strains. Studies were undertaken to assess the suitability of a freeze-dried pool of human anti-JE plasma, collected from recipients of Biken (Nakayama-NIH) killed vaccine, to serve as an International Standard for antibodies to JE virus. Five participants in five countries submitted data from 11 assays on the candidate International Standard and seven coded samples including sera from recipients of vaccines containing a range of virus strains. The results of the study indicated that the 50% plaque reduction neutralization test (PRNT50titres) obtained for serum from recipients of killed vaccines, including the candidate standard, vary depending on the virus strain used in the neutralization tests, namely higher PRNT50titres were obtained when the challenge virus was homologous to the vaccine strain compared to use of a heterologous virus. Potencies expressed relative to the candidate standard are therefore affected by the strain of virus used in assays and the use of a standard would therefore not facilitate direct comparison of data from laboratories that have used different challenge strains.

KW - Antibody

KW - Japanese encephalitis virus

KW - Neutralization

KW - Standardization

KW - Strains

UR - http://www.scopus.com/inward/record.url?scp=39549093764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39549093764&partnerID=8YFLogxK

U2 - 10.1016/j.biologicals.2007.07.002

DO - 10.1016/j.biologicals.2007.07.002

M3 - Article

VL - 36

SP - 111

EP - 116

JO - Biologicals

JF - Biologicals

SN - 1045-1056

IS - 2

ER -